Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies

Neurobiology of Disease

Volumn 94, Issue , 2016, Pages 18-31

  Combs, Benjamin ^a   Hamel, Chelsey ^a   Kanaan, Nicholas M ^a,b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Hauenstein Neuroscience Center   (United States)

Author keywords

Alzheimer's disease; Antibodies; Conformation; Neurodegeneration; Protein aggregation; Protein misfolding; Tau; Tauopathies

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TAU PROTEIN; TAU12 PROTEIN; TAU13 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BIOASSAY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE MARKER; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MALE; MOLECULAR EVOLUTION; MOLECULAR RECOGNITION; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PHOSPHATASE ACTIVATING DOMAIN; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN LOCALIZATION; RAT; TISSUE SECTION; ANIMAL; DISEASE EXACERBATION; METABOLISM; NERVE CELL; NERVE FIBER TRANSPORT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; AXONAL TRANSPORT; DISEASE PROGRESSION; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; TAUOPATHIES;

EID: 84973572645     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.05.016     Document Type: Article

References (50)

1. Augustinack J.C., et al. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.) 2002, 103:26-35.
2. Bancher C., et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989, 477:90-99.
3. Bancher C., et al. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res. 1991, 539:11-18.
4. Berry R.W., et al. Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. J. Neurocytol. 2004, 33:287-295.
5. Bobinski M., et al. Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:414-420.
6. Bondareff W., et al. Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1994, 53:158-164.
7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
8. Braak E., et al. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. (Berl.) 1994, 87:554-567.
9. Brandt R., et al. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell Biol. 1995, 131:1327-1340.
10. Bussiere T., et al. Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer's disease. Neuroscience 2003, 117:577-592.
11. Carmel G., et al. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 1996, 271:32789-32795.
12. Dickson D.W., et al. Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathol. 1992, 84:596-605.
13. Endoh R., et al. Lack of the carboxyl terminal sequence of tau in ghost tangles of Alzheimer's disease. Brain Res. 1993, 601:164-172.
14. Gamblin T.C. Potential structure/function relationships of predicted secondary structural elements of tau. Biochim. Biophys. Acta 2005, 1739:140-149.
15. Gamblin T.C., et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 2000, 39:6136-6144.
16. Garcia-Sierra F., et al. The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old. Acta Neuropathol. (Berl.) 2000, 100:29-35.
17. Garcia-Sierra F., et al. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J. Alzheimers Dis. 2003, 5:65-77.
18. Ghoshal N., et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 2002, 177:475-493.
19. Goedert M., et al. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995, 189:167-169.
20. Gomez-Isla T., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
21. Greenberg S.G., et al. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 1992, 267:564-569.
22. Guo H., et al. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 2004, 165:523-531.
23. Hollander Z., Katchalski-Katzir E. Use of monoclonal antibodies to detect conformational alterations in lactate dehydrogenase isoenzyme 5 on heat denaturation and on adsorption to polystyrene plates. Mol. Immunol. 1986, 23:927-933.
24. Horowitz P.M., et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J. Neurosci. 2004, 24:7895-7902.
25. Horowitz P.M., et al. N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry 2006, 45:12859-12866.
26. Hyman B.T., et al. Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann. Neurol. 1988, 23:371-379.
27. Jeganathan S., et al. Global hairpin folding of tau in solution. Biochemistry 2006, 45:2283-2293.
28. Jeganathan S., et al. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 2008, 283:32066-32076.
29. Jicha G.A., et al. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 1997, 48:128-132.
30. Jicha G.A., et al. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J. Neurosci. Res. 1999, 55:713-723.
31. Kanaan N.M., et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 2011, 31:9858-9868.
32. Kanaan N.M., et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol. Aging 2012, 33(826):e15-e30.
33. Kanaan N.M., et al. Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy. J. Neuropathol. Exp. Neurol. 2015.
34. Kapuscinski J. DAPI: a DNA-specific fluorescent probe. Biotech. Histochem. 1995, 70:220-233.
35. LaPointe N.E., et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 2009, 87:440-451.
36. Luna-Munoz J., et al. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 2007, 12:365-375.
37. Mena R., et al. Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. Acta Neuropathol. 1995, 89:50-56.
38. Mercken M., et al. Monoclonal antibodies with selective specificity for Alzheimer tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992, 84:265-272.
39. Morsch R., et al. Neurons may live for decades with neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 1999, 58:188-197.
40. Mukrasch M.D., et al. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol. 2009, 7.
41. Otvos L., et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 1994, 39:669-673.
42. Papasozomenos S.C., Binder L.I. Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil. Cytoskeleton 1987, 8:210-226.
43. Patterson K.R., et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem. 2011, 286:23063-23076.
44. Patterson K.R., et al. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry. 2011, 50:10300-10310.
45. Petry F.R., et al. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. PLoS One 2014, 9.
46. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
47. Shields M.J., et al. An appraisal of polystyrene-(ELISA) and nitrocellulose-based (ELIFA) enzyme immunoassay systems using monoclonal antibodies reactive toward antigenically distinct forms of human C-reactive protein. J. Immunol. Methods 1991, 141:253-261.
48. Spires-Jones T.L., et al. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J. Neurosci. 2008, 28:862-867.
49. Wittmann C.W., et al. Tauopathy in drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
50. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.